Intensity of the vaccine-elicited immune response determines tumor clearance

Journal of Immunology

Volumn 168, Issue 1, 2002, Pages 338-347

  Perez Diez, A ^a   Spiess, P J ^a   Restifo, N P ^a   Matzinger, P ^a   Marincola, F M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNOLOGY; VACCINATION; VIRUS RECOMBINANT;

EID: 0036136256     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.1.338     Document Type: Article

References (39)

1. Tumor antigens recognized by T cells
2. Cancer vaccines based on the identification of genes encoding cancer regression antigens
3. New paths in human cancer serology
4. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MARTl/Melan A
5. Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers and beyond
6. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
7. + cancers
8. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
9. Impact of cytokine administration on the generation of anti-tumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
10. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
11. Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion
12. Functional analysis of antigenspecific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
13. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases
14. A shift in the phenotype of MelanA-specific CTL identifies melanoma patients with an active tumor-specific immune response
15. + T cells
16. Clonal analysis of cytotoxic T cell response against human melanoma
17. Assessment of tumor specific immune reactivity in patients receiving immunization with the MART-1 melanoma antigen immunodominant peptide
18. Principles of immune monitoring in cancer vaccine trials
19. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
20. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
21. Active immunotherapy of cancer with a nonreplicating recombinant fowl-pox virus encoding a model tumor-associated antigen
22. Fluorescence activated cell analysis and sorting of viable mammalian cells based on β-D-galactosidase activity after transduction of Escherichia coli LacZ
23. Real time quantitative PCR
24. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo
25. Immune surveillance against a solid tumor fails because of immunological ignorance
26. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
27. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
28. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
29. Melanoma cell expression of Fas (Apo-I/CD95) ligand: Implications for tumor immune escape
30. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
31. The influence of graft size on the induction of immunity versus tolerance to H-Y in H-2k strains of mice
32. Studies on the behavior of H-Y incompatible skin grafts in rats
33. Differential requirement of perforin and IFN-γ in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen
34. IFN-γ and tumor necrosis factor-α: Cytotoxicity to murine islets of Langerhans
35. Malaria elicit type I cytokines in the human placenta: IFN-γ and TNF-α associated with pregnancy outcomes
36. Transgenic mice expressing IFN-γ in the retina develop inflammation of the eye and photoreceptor loss
37. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
38. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma
39. Kinetics of TCR use in response to repeated epitope-specific immunization